Literature DB >> 10155599

Quality of life in cystic fibrosis.

D E Tullis1, G H Guyatt.   

Abstract

Cystic fibrosis is a chronic, multisystem genetic disease with a wide variability in clinical severity. In recent years, advances in therapy have led to improved patient survival into adulthood. New treatments are rapidly being developed and require evaluation to determine their efficacy. The measurement of health-related quality of life in cystic fibrosis provides additional information about the impact of this disease that cannot be obtained by physiological tests such as pulmonary function. An instrument to measure health-related quality of life is especially useful as an outcome measure for clinical trials. To date, only a few general quality-of-life (QOL) measures have been used in people with cystic fibrosis. There has been some demonstration of validity in 2 measures (the Quality of Well-Being Scale and the Functional Status Index) but the responsiveness of these instruments in this population has not been established. A cystic fibrosis-specific QOL instrument would be valuable as an outcome measure because of its potential for increased responsiveness, but no published measures exist as yet.

Entities:  

Mesh:

Year:  1995        PMID: 10155599     DOI: 10.2165/00019053-199508010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  43 in total

1.  Comparison of Quality of Well-Being scale and Functional Status Index in patients with atrial fibrillation.

Authors:  T G Ganiats; L A Palinkas; R M Kaplan
Journal:  Med Care       Date:  1992-10       Impact factor: 2.983

2.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

3.  Functional status as an overall measure of health in adults with cystic fibrosis: further validation of a generic health measure.

Authors:  S L Shepherd; M F Hovell; D J Slymen; I R Harwood; C R Hofstetter; L E Granger; R M Kaplan
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

4.  Survival and quality of life of cystic fibrosis patients before and after heart-lung transplantation.

Authors:  N Caine; L D Sharples; R Smyth; J Scott; T Hathaway; T W Higenbottam; J Wallwork
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  Water and electrolytes in cervical mucus from patients with cystic fibrosis.

Authors:  L E Kopito; H J Kosasky; H Shwachman
Journal:  Fertil Steril       Date:  1973-07       Impact factor: 7.329

6.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

Review 7.  NHLBI workshop summary. Clinical-behavioral aspects of cystic fibrosis: directions for future research.

Authors:  H Eigen; N M Clark; J M Wolle
Journal:  Am Rev Respir Dis       Date:  1987-12

8.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

10.  Measuring the quality of well-being in cystic fibrosis and lung transplantation. The importance of the area under the curve.

Authors:  D M Orenstein; R M Kaplan
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

View more
  7 in total

Review 1.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients.

Authors:  Bernadette Henry; Pierre Aussage; Cécile Grosskopf; Jean-Marie Goehrs
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

3.  Measuring the health related quality of life of people with ischaemic heart disease.

Authors:  M Dempster; M Donnelly
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 4.  Measuring quality of life in paediatric patients.

Authors:  M A Connolly; J A Johnson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 5.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Quality of life in patients with cystic fibrosis and their parents: what is important besides disease severity?

Authors:  D Staab; K Wenninger; N Gebert; K Rupprath; S Bisson; M Trettin; K D Paul; K M Keller; U Wahn
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 7.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.